

Droxinostat

Catalog No: tcsc0491



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

99873-43-5

Formula:

$C_{11}H_{14}ClNO_3$

Pathway:

Epigenetics;Cell Cycle/DNA Damage

Target:

HDAC;HDAC

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 150 mg/mL (615.54 mM)

Alternative Names:

NS 41080

Observed Molecular Weight:

243.69

Product Description


Droxinostat(NS41080) is a selective inhibitor of HDAC3, HDAC6, and HDAC8 with IC₅₀ of 16.9, 2.47 and 1.46 μ M, respectively; > 8-fold selective against HDAC3 and no inhibition to HDAC1, 2, 4, 5, 7, 9, and 10.

IC₅₀ Value: 16.9 μ M(HDAC3); 2.47 μ M(HDAC6); 1.46 μ M(HDAC8)

Target: HDAC3/6/8

in vitro: Droxinostat is originally identified as a sensitizer of PPC-1 cells to FAS and TRAIL by downregulating the expression of c-Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein (c-FLIP). the direct targets of Droxinostat remains enigma until recently. It is revealed that in histone deacetylases (HDAC) isoform 1-10, Droxinostat selective inhibits HDAC3, 6, and 8, with IC₅₀ values of 16.9 μ M, 2.47 μ M, and 1.46 μ M, respectively, without inhibiting other HDAC members (IC₅₀ > 20 μ M). In MCF-7 breast cancer cells, Droxinostat (10 μ M–100 μ M) sensitizes cells to apoptosis by decreasing c-FLIPL and c-FLIPS expression, reducing cell survival, and inducing apoptosis.

in vivo: In SCID mice models, Droxinostat (30 μ M)-treated PPC-1 cells results in decreased distant tumor formation than untreated cells.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!